



## Fetal Well Being

Click the next button to continue...



Copyright © 2020 Shelly Betancourt and Michelle Becher

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. For permission requests, write to the publisher at the address below.

Maternal 911 Education Systems, LLC  
475 West Center St.  
Ithaca, MI 48847  
[www.maternal911.com](http://www.maternal911.com)

Maternal 911 and Maternal 911 in Action contains information designed as an educational resource to aid practitioners in providing obstetric care and the use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgement. Maternal 911 reviews the publication regularly, but may not reflect the most recent evidence.

Maternal 911 makes every effort to present accurate and reliable information. The Maternal 911 and Maternal 911 in Action are publications provided 'as is' without any warranty of accuracy, reliability or otherwise, either express or implied. Maternal 911 does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither co-founder nor any officers, directors, members, employees, participants, or agents will be liable for any loss, damage or claim with respect to liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Data from completing the modules may be used in research and publications with privacy maintained.

**Course Description:**

This course will help the participants identify hypoxemia and acidosis in an unborn fetus based upon fetal heart rate (FHR) monitoring to avoid fetal neurologic injury. The participants will be aware of measures needed to ensure a safe outcome so measures can be rapidly implemented.

**Approximate Time to Complete:** 60 minutes





**This course will:**

- Help participants develop sound clinical judgment in the delivery of health care setting when concerns are suspected in regards to fetal well-being.
- Expand participant's knowledge base on learning theories and their instructional implications regarding health care delivery setting when fetal well-being is questionable.
- Enable participants to develop, implement, and evaluate health care delivery in a practice setting prior to an actual event. This will allow for early recognition of an actual event.
- Enhance participant's ability to put knowledge into active health care delivery. This will allow for rapid implementation of the necessary steps needed when fetal well-being is questionable.
- Prepare participants to address issues and implement changes in the health care unit as necessary to ensure a safe environment. Equipment and supplies needed when fetal well-being is questionable.



-  Definition
-  Goal
-  Modalities
-  Candidates for Monitoring
-  Definitions of FHR Characteristics
-  Interpretation
-  Evaluation of Category I and II Tracings
-  Instrumentation
-  Instrumentation: Non-invasive Fetal Monitoring
-  Instrumentation: Invasive Fetal Monitoring
-  Recommendations from National Organizations
-  Summary



The rationale for monitoring the FHR during labor is that heart rate patterns are indirect markers of the fetal cardiac and central nervous system (CNS) response to blood volume changes, acidemia, and hypoxemia, since the brain modulates heart rate.

Nearly all obstetric societies advise monitoring the FHR during labor.

This position is chiefly based upon medical and legal opinion with neither continuous electronic fetal monitoring (EFM) or intermittent auscultation proven beneficial in low risk pregnancies.



The primary goal of intrapartum FHR monitoring is to identify hypoxemic and acidotic fetuses in whom timely intervention will prevent death. The American College of Obstetricians and Gynecologists (ACOG) recommends antepartum fetal surveillance for pregnancies when risk of fetal demise is increased [1].

**These pregnancies include but are not limited to:**

- ✓ Diabetes
- ✓ Hypertensive disorders
- ✓ Fetal growth restriction
- ✓ Multiple gestation
- ✓ Post-term pregnancy
- ✓ Decreased fetal movement
- ✓ Systemic lupus erythematosus
- ✓ Antiphospholipid syndrome
- ✓ Sickle cell disease

- ✓ Alloimmunization
- ✓ Oligohydramnios
- ✓ Polyhydramnios
- ✓ Prior fetal demise
- ✓ Nonimmune hydrops
- ✓ Maternal heart disease
- ✓ Poorly controlled maternal hyperthyroidism
- ✓ Maternal vascular diseases
- ✓ Preterm premature rupture of membranes (PPROM)



**Other possible health conditions that are indicators for antenatal testing:**

- Advanced maternal age
- Obesity
- Major fetal anomalies
- Abnormal first and second trimester screening results [2,3]

Testing should begin when risk of fetal demise is identified. Observational data has shown in non-growth restricted fetuses, that increased risk occurs at 32 to 34 weeks through term pregnancy, so 32 weeks of gestation has become a common time to initiate fetal surveillance [4].


There is no data that recommends daily, every other day, twice weekly, or once weekly fetal monitoring. The decision on frequency is based on expert opinion and clinical experiences. Surveillance may begin weekly, then increase to twice weekly in some situations.

There is some evidence that intrapartum fetal monitoring achieves a reduction in intrapartum death [1] but no evidence of a reduction in long-term neurologic impairment [5].

Intrapartum FHR evaluation is achieved through continuous electronic FHR monitoring and intermittent auscultation.


In initial FHR monitoring studies, comparison between intermittent auscultation with no monitoring and intermittent auscultation with monitoring, intermittent auscultation did not demonstrate a decrease in perinatal mortality or neurologic disabilities [6-8].

No trials have compared continuous electronic fetal monitoring with no monitoring.



For both low- and high-risk pregnancies, there is no convincing evidence that continuous electronic FHR monitoring performs better than intermittent auscultation and consistent evidence that electronic fetal monitoring has a high false positive rate for predicting adverse outcomes [6-8].

A 2017 systematic review of 13 randomized trials, including >37,000 low and high risk pregnancies, a comparison of continuous electronic FHR monitoring with intermittent auscultation found no compelling differences between techniques in the following events [8]:

- 
- 
- Perinatal mortality
  - Cerebral palsy
  - Acidosis measured in cord blood
  - Hypoxic ischemic encephalopathy
  - Neurodevelopmental impairment at  $\geq 12$  months of age
  - Apgar score  $< 4$  at five minutes
  - Neonatal intensive care unit (NICU) admission
- 
- 

Fewer neonatal seizures were noted with continuous electronic FHR monitoring, but the seizures prevented by this monitoring were not associated with long-term sequela [8,9].

Use of continuous electronic FHR monitoring also resulted in more cesarean and operative vaginal deliveries for abnormal FHR patterns (RR 2.38 [95% CI 1.89-3.01] and RR 2.54 [95% CI 1.95-3.31], respectively), and, in turn, fewer spontaneous vaginal births (RR 0.91, 95% CI 0.86-0.96) [8,9].

Data for low- and high-risk subgroups, preterm pregnancies, and high-quality trials were consistent with these overall results [8].




[Click here to see more information.](#)



Fortunately, perinatal death is a rare occurrence; so interpretation of a reduction in death rate is difficult to validate [8].

In a 2017 meta-analysis, pooled results from a number of randomized trials had limited evidence to provide a reliable conclusion [8].

However, a prior meta-analysis that evaluated perinatal deaths related to fetal hypoxia in both low- and high-risk pregnancies, electronic monitoring demonstrated a reduction in deaths due to hypoxia when compared to intermittent auscultation [5].





There are many reasons why it is difficult to identify a reduction in cerebral palsy:


- Intrapartum interventions are not likely to change the course of cerebral palsy because most cases are due to an antepartum event [6].
- In a study, cerebral palsy was not associated with an abnormal FHR in 99.8 percent of tracing [6].
- Furthermore, a fetal neurologic disorder may be the cause, rather than the result, of FHR abnormalities [10].
- Rather than survive with disabilities, most severely depressed term fetuses survive intact or die [11].

Some maternal and fetal conditions have an increased risk of adverse fetal/neonatal outcomes; however, there is no convincing evidence that continuous FHR monitoring reduces this risk.

Nevertheless, some type of FHR monitoring during labor has become routine for all women in the United States and will probably not be abandoned because most patients and clinicians are reassured by normal results and believe there is some value in detecting abnormal patterns.

Most are willing to accept an increase in cesarean and operative vaginal births associated with continuous electronic fetal monitoring, which is estimated to be an extra 12 cesareans and 25 operative deliveries per 1000 births [5].

In addition, economic issues preclude hospitals' ability to provide 1:1 nurse:patient staffing, which is needed for monitoring by intermittent auscultation.





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Variability**

- Baseline fluctuations that are irregular in amplitude and frequency
- Absent = amplitude undetectable
- Minimal = amplitude 0 to 5 beats per minute (bpm)
- Moderate = amplitude 6 to 25 bpm
- Marked = amplitude over 25 bpm

Late Deceleration

Early Deceleration

Variable Deceleration

Prolonged Deceleration



*Click each characteristic to see the definitions.*





Variability

10 Minute Window

Baseline Rate

Acceleration

## National Institute of Child Health and Human Development (NICHD) Definitions of FHR Characteristics

### Measured in a 10-minute Window

- The amplitude is measured peak to trough, defining baseline fetal heart rate variability in the following classification:
  - In any given 10-minute window, the minimum baseline duration must be at least 2 minutes or else the baseline is considered indeterminate. When this occurs, the previous 10-minute window should be reviewed and utilized to determine the baseline.
  - Uterine contractions are quantified by the number of contractions present in a 10-minute window, averaged over a 30 minute period.

| Amplitude Range                    | Classification |
|------------------------------------|----------------|
| Undetectable                       | Absent         |
| Undetectable to $\leq 5$ beats/min | Minimal        |
| 6-25 beats/min                     | Moderate       |
| $>25$ beats/min                    | Marked         |

- There is no distinction between short- and long-term variability.

Late Deceleration

Early Deceleration

Variable Deceleration

Prolonged Deceleration



Click each characteristic to see the definitions.





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Baseline Rate**

- Bradycardia = below 110 bpm
- Normal = 110 to 160 bpm
- Tachycardia = over 160 bpm
- The baseline rate is the mean bpm (rounded to 0 or 5) over a 10 minute interval, excluding periodic changes, periods of marked variability, and segments that differ by more than 25 bpm.
- The baseline must be identifiable for 2 minutes during the interval, but does not need to be a contiguous 2 minutes.
- If the baseline rate is not identifiable for 2 minutes, it is considered indeterminate.

**Late Deceleration**

**Early Deceleration**

**Variable Deceleration**

**Prolonged Deceleration**



*Click each characteristic to see the definitions.*





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Acceleration**

- An abrupt increase in the FHR.
- Before 32 weeks of gestation, accelerations should last >10 seconds and peak at >10 bpm above baseline.
- As of 32 weeks gestation, accelerations should last >15 seconds and peak at >15 bpm above baseline.
- A prolonged acceleration is  $\geq 2$  minutes but less than 10 minutes.
- When an acceleration lasts for 10 minutes or more, it is considered a change in FHR baseline.

**Late Deceleration**

**Early Deceleration**

**Variable Deceleration**

**Prolonged Deceleration**



*Click each characteristic to see the definitions.*





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Late Deceleration**

- A gradual decrease and return to baseline of the FHR associated with a uterine contraction.
- The deceleration is delayed in timing, with the nadir of the deceleration occurring after the peak of the contraction.
- The onset, nadir, and recovery usually occur after the onset, peak, and termination of a contraction.

Late Deceleration

Early Deceleration

Variable Deceleration

Prolonged Deceleration



*Click each characteristic to see the definitions.*





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Early Deceleration**

- A gradual decrease and return to baseline of the FHR associated with a uterine contraction.
- The nadir of the FHR and the peak of the contraction occur at the same time.
- The deceleration's onset, nadir, and termination are usually coincident with the onset, peak, and termination of the contraction.

Late Deceleration

Early Deceleration

Variable Deceleration

Prolonged Deceleration



*Click each characteristic to see the definitions.*





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Variable Deceleration**

- An abrupt decrease in FHR below the baseline. The decrease is  $\geq 15$  bpm, lasting  $\geq 15$  secs and  $< 2$  minutes from onset to return to baseline.
- The onset, depth, and duration of variable decelerations commonly vary with successive uterine contractions.

Late Deceleration

Early Deceleration

Variable Deceleration

Prolonged Deceleration



*Click each characteristic to see the definitions.*





Variability

10 Minute Window

Baseline Rate

Acceleration

**National Institute of Child Health and Human Development (NICHD)**  
Definitions of FHR Characteristics

**Prolonged Deceleration**

- A decrease in FHR below the baseline of 15 bpm or more, lasting at least 2 minutes but <10 minutes from onset to return to baseline.
- A prolonged deceleration of 10 minutes or more is considered a change in baseline.

Late Deceleration

Early Deceleration

Variable Deceleration

Prolonged Deceleration





### Minimal Variability with Recurrent Decelerations

- Minimal variability is thought to result from cerebral hypoxemia and acidosis, and signifies failure of fetal compensatory mechanisms to maintain adequate oxygenation of the brain [12].
- It may be accompanied by recurrent or prolonged decelerations [12].
- The likelihood of fetal acidemia increases in tandem with increases in the frequency, depth, and duration of the decelerations [13].
- If variable decelerations occur with at least 50% of uterine contractions in a 20 minute window they are considered recurrent [12,15].

## Recurrent Late Decelerations

- Late decelerations are caused by the reflex CNS response to transient hypoxia and acidemia caused by uterine contractions, as well as direct myocardial depression and humoral factors [14].
- If late decelerations occur with at least 50% of uterine contractions in a 20 minute window they are considered recurrent [12,15].



*Click each link to see the waveforms.*

[Waveform 1](#)



[Waveform 2](#)

[Waveform 3](#)

[Waveform 4](#)



# Waveform 1 - Late Decelerations



50010


REORDER M1910A

PHILIPS


50020

REORDER M1910A


# Waveform 2 - Late Decelerations



# Waveform 3 - Deep Late Decelerations




# Waveform 4 - Recurrent Late Decelerations



### Recurrent Variable Decelerations

- Variable decelerations occur when the umbilical cord is compressed, which may happen during a contraction in the setting of oligohydramnios or a nuchal cord.
- The thin walled umbilical vein is more sensitive to compression than the umbilical arteries.
- This results in variable effects on fetal preload and afterload, which lead to changes in FHR mediated by baroreceptors, and by chemoreceptors when there is sufficient hypoxemia.
- Intermittent variable decelerations are frequently observed in labor tracings and are not usually associated with adverse consequences, presumably because transient cord compression is well tolerated by the fetus.



### Recurrent Variable Decelerations Continued

- In sleep studies, fetal metabolic acidosis or mixed metabolic and respiratory acidosis developed with increasing duration, depth, and frequency of variable decelerations [16-17].
- In a human study, pH fell when the decelerations had delayed recovery and when they were deeper than 60 bpm, but only 18% of newborns with these findings had a low Apgar score at 1 minute and none had a low score at 5 minutes [18].



Mouse over Waveform 5 to enlarge the image.



# Waveform 5 - Recurrent Variable Decelerations



## Variable Decelerations


- There are many atypical variations, particularly with this type of deceleration, which is inherently variable ([Waveform 6](#) and [Waveform 7](#)) [17].
- The body of evidence does not support attaching clinical significance to atypical features:
  - Variable decelerations with lambda or W pattern (biphasic deceleration),
  - Loss of primary or secondary acceleration (shoulders),
  - Persistent secondary acceleration (overshoot), or
  - Reduction in post-deceleration baseline [12]
- The NICHD classification does not include atypical variable decelerations as a category of FHR pattern [12].
  - However, it does consider variable decelerations with absent baseline variability as predictive of acidosis.



*Click the links above to see the Waveforms.*



# Waveform 6 - Variable Decelerations




PHILIPS

56303

REORDER M1910A


REORDER M1910A

# Waveform 7 - Variable Decelerations with Minimal to Absent Variability





## Prolonged Decelerations




- A deceleration below 110 bpm with minimal variability is abnormal when it occurs for a prolonged period of time (i.e., 2 to 10 minutes) in the absence of hypothermia, complete heart block, or use of causative maternal medication (e.g., beta-adrenergic blockers, paracervical block).
- When the FHR falls below 100, tissue perfusion may not be adequate.
- This degree of bradycardia is abnormal even when variability is present since it may be due to an acute adverse event.



*Click the heart to see more information.*



**Sinusoidal Heart Rate Pattern** — A sinusoidal FHR pattern resembles a smooth sine wave, with periodicity of 3 to 5 cycles per minute and lasting for at least 20 minutes ([Waveform 8](#)) [12].





- Beat to beat changes are often small, but in the same direction, creating the wave pattern.
- Decelerations and accelerations in response to movement are absent.
- The mechanism for the sinusoidal pattern is believed to be a response to moderate fetal hypoxemia, often secondary to fetal anemia.
- A sinusoidal-like pattern has also been associated with physiological changes in fetal peripheral arterial resistance, fetal sucking movements, and maternal opioid administration [18-22].



*Click the link above to see the waveform.*



# Waveform 8 - Sinusoidal Pattern



PHILIPS

56016

REORDER M1910A

PHILIPS



**NICHD classification** — Interpretation of FHR tracings is subjective and not very reproducible.

- Studies have consistently shown that there is large inter- and intra-observer variability in interpretation of electronic FHR monitoring tracings [23-29].
- For this reason, ACOG, the Society for Maternal-Fetal Medicine (SMFM), and the United States NICHD assembled a workshop to create standardized definitions and interpretation for EFM [30].
- The definitions tabulated in the prior slides have been endorsed by the ACOG and are used clinically [30].
- These definitions do not apply to computer generated FHR interpretations, and European standards differ from those in the United States.
- Observer agreement remains controversial because of disagreement between absent versus minimal variability and characterization of decelerations [24,31].
- Following NICHD standardization, the International Federation of Gynecology and Obstetrics (FIGO) and others have created similar guidelines [32].





The NICHD subsequently created a three-tier FHR interpretation system ([Table 2](#)):

**Category I** represents a normal tracing predictive of normal fetal acid-base balance at the time of observation

**Category II** represents an indeterminate tracing that is neither Category I nor Category II.

**Category III** represents an abnormal tracing predictive of a significant incidence of abnormal fetal acid-base status at the time of observation [12].

Evidence suggests improved neonatal outcomes with standardized approach to pattern recognition with standardized therapeutic interventions ([Table 3](#)) [33].



Click the links to see each table.



| <b>Category</b>           | <b>Interpretation</b>  | <b>Features</b>   |
|---------------------------|--|---|
| <b>I - Normal</b>         | Strongly predictive of normal acid-base status at this time of observation   | <ul style="list-style-type: none"> <li>• Baseline FHR 110-160 bpm</li> <li>• Baseline FHR variability moderate 6 to 25 bpm</li> <li>• Late or variable FHR decelerations are absent</li> <li>• Early FHR decelerations are present or absent</li> </ul>   |
| <b>II - Indeterminate</b> | Not predictive of abnormal acid-base status, however there are insufficient data to classify as either Category I or III | <p>All FHR tracings not categorized as Category I or III may represent many tracings that are encountered in everyday clinical practice.</p> <p>Examples:</p> <ul style="list-style-type: none"> <li>• Minimal variability</li> <li>• Absent variability without recurrent decelerations</li> <li>• Marked variability</li> <li>• Absent of induced accelerations after fetal stimulation</li> <li>• Prolonged deceleration</li> <li>• Recurrent late decelerations with moderate variability</li> <li>• Variable decels with "slow return to baseline," "overshoots" or "shoulders"</li> </ul> |
| <b>III - Abnormal</b>     | Predictive of abnormal acid-base status at time of observation   | <p>Absent FHR variability AND any of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent late FHR decelerations</li> <li>• Recurrent variable FHR decelerations</li> <li>• FHR bradycardia</li> <li>• Sinusoidal FHR pattern</li> </ul>   |

| <b>Goal</b>   | <b>FHR Abnormality</b>  | <b>Intervention</b>  |
|---|---|--|
| <b>Promote fetal oxygenation and improve blood flow to the uterus</b> | <ul style="list-style-type: none"> <li>• Recurrent late decelerations</li> <li>• Prolonged decelerations</li> <li>• Fetal bradycardia</li> <li>• Minimal or absent variability</li> </ul> | <ul style="list-style-type: none"> <li>• Reposition the woman in a lateral position. If in a lateral position, change her to the other side.</li> <li>• Oxygen (O<sub>2</sub>) administration</li> <li>• Intravenous (IV) fluid bolus</li> <li>• Reduce frequency of uterine contractions</li> </ul> |
| <b>Reduce uterine activity</b>  | <ul style="list-style-type: none"> <li>• Tachysystole with Category II or III tracing</li> </ul>  | <ul style="list-style-type: none"> <li>• Discontinue oxytocin or cervical ripening agents</li> <li>• Administer tocolytic medication</li> </ul>  |
| <b>Alleviate umbilical cord compression</b>                           | <ul style="list-style-type: none"> <li>• Recurrent variable decelerations</li> <li>• Prolonged deceleration</li> <li>• Fetal bradycardia</li> </ul>                                       | <ul style="list-style-type: none"> <li>• Reposition the woman in a lateral or knee-chest position</li> <li>• Perform amnioinfusion</li> <li>• If cord prolapse, keep presenting fetal part elevated away from the cord</li> </ul>  |
| <b>Normalize maternal hypotension</b>                                 | <ul style="list-style-type: none"> <li>• Recurrent late decelerations</li> <li>• Prolonged decelerations</li> <li>• Fetal bradycardia</li> <li>• Category II or III tracings</li> </ul>   | <ul style="list-style-type: none"> <li>• Lateral position</li> <li>• IV fluids</li> <li>• If FHR not improving with other interventions, consider Ephedrin 5.0 to 10.0mg intravenous push (IVP)</li> </ul>   |


It is practical to consider absent and minimal variability to be of similar pathophysiology and to manage them in the same way [34].

Although severe fetal acidemia is most reliably predicted by absent FHR variability, there is significant interobserver variation in diagnosing absent versus minimal variability [26].

The fetus with normal FHR variability who cannot compensate for progressive and/or repetitive hypoxemic episodes may not abruptly develop significant acidosis or absent variability.

The changes in variability and pH occur over a period of time in the absence of an acute catastrophic event.

The point at which variability diminishes from minimal to absent can be difficult to determine, especially when variable decelerations and/or technical artifact are present.





## CATEGORY I

Category I tracings — A Category I tracing is reassuring as it indicates there is minimal likelihood of acidemia **at that point in time**.

- It is not predictive of future status, as tracing patterns can change.
- A Category I tracing has all of the following components:
  - A baseline FHR of 110 to 160 bpm
  - No late or variable FHR decelerations
  - Moderate FHR variability (6 to 25 bpm)
  - Early decelerations ([Waveform 10](#))
  - See [Table 2](#) and [Waveform 9](#) [10].

Click for more on  
Category 1

## CATEGORY II

## CATEGORY III



*You must click each link above to learn more before you can select a different category.*




*Click each dark blue category button as they appear to learn more.*




| <b>Category</b>           | <b>Interpretation</b>  | <b>Features</b>   |
|---------------------------|--|---|
| <b>I - Normal</b>         | Strongly predictive of normal acid-base status at this time of observation   | <ul style="list-style-type: none"> <li>• Baseline FHR 110-160 bpm</li> <li>• Baseline FHR variability moderate 6 to 25 bpm</li> <li>• Late or variable FHR decelerations are absent</li> <li>• Early FHR decelerations are present or absent</li> </ul>   |
| <b>II - Indeterminate</b> | Not predictive of abnormal acid-base status, however there are insufficient data to classify as either Category I or III | <p>All FHR tracings not categorized as Category I or III may represent many tracings that are encountered in everyday clinical practice.</p> <p>Examples:</p> <ul style="list-style-type: none"> <li>• Minimal variability</li> <li>• Absent variability without recurrent decelerations</li> <li>• Marked variability</li> <li>• Absent of induced accelerations after fetal stimulation</li> <li>• Prolonged deceleration</li> <li>• Recurrent late decelerations with moderate variability</li> <li>• Variable decels with "slow return to baseline," "overshoots" or "shoulders"</li> </ul> |
| <b>III - Abnormal</b>     | Predictive of abnormal acid-base status at time of observation   | <p>Absent FHR variability AND any of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent late FHR decelerations</li> <li>• Recurrent variable FHR decelerations</li> <li>• FHR bradycardia</li> <li>• Sinusoidal FHR pattern</li> </ul>   |

# Waveform 9 - Category I



# Waveform 10 - Early Deceleration

FHR: DEC5 FHR2





## CATEGORY I

## CATEGORY II

## CATEGORY III

### Category I Tracings

- Accelerations may be present or absent.
- FHR accelerations are an important finding when present because their presence, especially with moderate variability, almost always indicates that the fetus is not acidotic [12,35-37].
- Deviation from a normal baseline and periodic changes associated with contractions are not abnormal in the continuum of the FHR tracing.
- Early decelerations (Table 1 and Waveform 10) are felt to be a vagal response due to fetal head compression.
- Early decelerations are not associated with fetal acidosis or poor neonatal outcome.
- The baseline FHR can be as low as 100 and be associated with the vagally mediated head compression.
- In a study of 48,000 women with a singleton normal fetus in term labor, 99% of the tracings demonstrated a Category I pattern at some point during labor [38].



*You must click each link above to learn more before you can select a different category.*



*Click each dark blue category button as they appear to learn more.*





## CATEGORY I

## CATEGORY II

## CATEGORY III

- Category II FHR tracings include all patterns that are not classified as category I or Category III. This pattern is neither normal or abnormal ([Table 2](#)).
- Fetal acidosis can vary with the different types of Category II tracings.
- Category II tracings are observed at some time in 84% of tracings and can remain stable for a prolonged period, making evaluation and management difficult [38].



*Click each dark blue category button as they appear to learn more.*



| <b>Category</b>           | <b>Interpretation</b>  | <b>Features</b>   |
|---------------------------|--|---|
| <b>I - Normal</b>         | Strongly predictive of normal acid-base status at this time of observation   | <ul style="list-style-type: none"> <li>• Baseline FHR 110-160 bpm</li> <li>• Baseline FHR variability moderate 6 to 25 bpm</li> <li>• Late or variable FHR decelerations are absent</li> <li>• Early FHR decelerations are present or absent</li> </ul>   |
| <b>II - Indeterminate</b> | Not predictive of abnormal acid-base status, however there are insufficient data to classify as either Category I or III | <p>All FHR tracings not categorized as Category I or III may represent many tracings that are encountered in everyday clinical practice.</p> <p>Examples:</p> <ul style="list-style-type: none"> <li>• Minimal variability</li> <li>• Absent variability without recurrent decelerations</li> <li>• Marked variability</li> <li>• Absent of induced accelerations after fetal stimulation</li> <li>• Prolonged deceleration</li> <li>• Recurrent late decelerations with moderate variability</li> <li>• Variable decels with "slow return to baseline," "overshoots" or "shoulders"</li> </ul> |
| <b>III - Abnormal</b>     | Predictive of abnormal acid-base status at time of observation   | <p>Absent FHR variability AND any of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent late FHR decelerations</li> <li>• Recurrent variable FHR decelerations</li> <li>• FHR bradycardia</li> <li>• Sinusoidal FHR pattern</li> </ul>   |

## CATEGORY I


## CATEGORY II

## CATEGORY III

A Category III tracing is considered abnormal and has increased occurrence of fetal hypoxia and metabolic acidemia.

- A category III tracing has absent FHR variability with [12]:
  - Recurrent late decelerations ([Waveform 4](#))
  - Recurrent variable decelerations ([Waveform 5](#))
  - Bradycardia
  - A sinusoidal pattern ([Waveform 8](#))
- To reduce the occurrence of fetal/neonatal morbidity or mortality, rapid recognition and evaluation with in utero resuscitation and/or delivery is necessary if the pattern persists [38].
- In a study of 48,000 women with a singleton normal fetus in term labor, 0.1% of the tracings demonstrated a Category III pattern at some point during labor [38].
- Tachycardia may be an ominous finding in the absence of variability.
- Category III tracings may be caused by health conditions unrelated to hypoxemia. A complete health history is necessary.


# Waveform 4 - Recurrent Late Decelerations



# Waveform 5 - Recurrent Variable Decelerations



# Waveform 8 - Sinusoidal Pattern





## Causes of Category II and III Tracings Unrelated to Hypoxemia

Other Etiologies:


### Fetal Arrhythmias

The credence correlation circuitry of the EFM represents signals interpreted as artifact with a pen lift, depicted as non-recording areas with internal and external FHR monitoring.

- The accompanying sound should be regarded as an unreliable signal, since it is generated by the same electronic mechanisms. However, some arrhythmias may present in this way.
- If there is uncertainty based on the FHR tracing, fetal echocardiography, sonographic, or non-sonographic approach should be considered as an alternative to the diagnosis, which may change the intrapartum management and treatment plan.
- There is generally no immediate threat to the fetus when intrapartum cardiac arrhythmias are present ([Waveform 11](#)).
- Fetal tachyarrhythmia can be benign or may cause heart failure or hydrops if prolonged.



## Waveform 11 - Cardiac Arrhythmia





## Causes of Category II and III Tracings Unrelated to Hypoxemia

Other Etiologies:

### Fetal Sleep Cycle

- Fetal sleep may last for 40 minutes and be noted with decreased FHR variability and fewer accelerations.

### Technical Factors

- Technical factors may include a malfunctioning leg plate, monitor cable, spiral electrode, or EFM. The EFM recording rate may be set to record at 1 cm/min instead of the standard 3cm/min. A very slow FHR may be doubled when recorded and a very fast rate >240 bpm may be halved by the equipment as a result of the computer algorithm.





## Causes of Category II and III Tracings Unrelated to Hypoxemia

Other Etiologies:

### Maternal Heart Rate Artifact

- Maternal artifact can interfere with accurate tracing of the FHR. The FHR is generally distinguished from the maternal rate because the FHR is faster [40].
- If FHR bradycardia is present, the rate may be similar to maternal rate as well, as fetal tachycardia may mimic maternal tachycardia due to elevated temperature, stress, or during uterine contractions [41-43].
- When the maternal heart rate is similar to FHR, as displayed on the EFM, further evaluation to distinguish maternal and fetal patterns should be performed.

*CONTINUED on next slide*





## Causes of Category II and III Tracings Unrelated to Hypoxemia

Other Etiologies:

### Maternal Heart Rate Artifact - Continued

- It is important to confirm that the external fetal monitor is actually recording the FHR and not the maternal heart rate transmitted from a maternal vessel, such as the aorta or uterine artery.
- An internal fetal electrode is not definitive, as a fetus that is recently dead can conduct the maternal cardiac signals through its body to the electrode [44].
- The simplest way to confirm that the FHR is being recorded is to confirm that the sound is not synchronous with the maternal pulse.
- Consider applying a pulse oximeter on the woman and comparing the rate to the FHR monitor tracing.
- Ultrasound examination of the fetal heart can be performed if there is continued uncertainty regarding fetal status.



## Causes of Category II and III Tracings Unrelated to Hypoxemia

Other Etiologies:

### Drug Effects

- Medication administered to the mother can pass through the placenta to the fetus and affect FHR.
- Decreased variability can be observed in the FHR tracing following maternal administration of opioids and magnesium sulfate.
- An increased FHR can be observed following maternal administration of atropine and a sinusoidal pattern following maternal administration of butorphanol [30].

### Congenital Anomalies

- Brady-arrhythmia can be observed on the FHR tracing when the fetus has a structural cardiac abnormality such as complete heart block.

### Maternal Fever

- FHR tracing may demonstrate changes when the woman has an increased temperature. Increased FHR baseline, tachycardia, and decreased variability may be noted.



## Causes of Category II and III Tracings Unrelated to Hypoxemia

Other Etiologies:

### Pre-Existing Fetal Neurologic Injury

- An antepartum neurologic injury can be suspected when an abnormal FHR pattern is present as soon as EFM is initiated.
- The most commonly observed FHR tracing present with neurologic injury is a non-reactive FHR and minimal or absent FHR variability with a persistent fixed FHR baseline [10,45].
- Be aware that antepartum neurologic injury can be present with a normal intrapartum FHR tracing [46].
- In studies of infants, an injury to the medulla oblongata or midbrain may be the cause of decreased or loss of FHR variability [47].




For improved neonatal outcome, FHR monitoring requires the health care provider to correctly recognize a Category I, II, and III tracing, communicate their interpretation with the health care team, and initiate appropriate and timely interventions [19,48].



## General Principles of Evaluation and Management Include:

The management of Category I, II, and III Tracing is summarized in [Table 3](#) and discussed in detail separately.

- Management of Category II and III Tracings are aimed at improving uteroplacental perfusion and maternal/fetal oxygenation.
- When possible, determine the likely cause of the abnormality:
  - Abruptio placenta
  - Cord prolapse
  - Tachysystole
  - Maternal medication
  - Malposition
  - Rapid descent of fetal head
- Reposition the patient onto her left or right side.
- Changing the maternal position may reduce cord compression and improve maternal blood flow to the placenta.
- The result is usually improved fetal gas exchange.



*Click the arrows  
to see more principles.*



| <b>Goal</b>   | <b>FHR Abnormality</b>  | <b>Intervention</b>  |
|---|---|--|
| <b>Promote fetal oxygenation and improve blood flow to the uterus</b> | <ul style="list-style-type: none"> <li>• Recurrent late decelerations</li> <li>• Prolonged decelerations</li> <li>• Fetal bradycardia</li> <li>• Minimal or absent variability</li> </ul> | <ul style="list-style-type: none"> <li>• Reposition the woman in a lateral position. If in a lateral position, change her to the other side.</li> <li>• Oxygen (O<sub>2</sub>) administration</li> <li>• Intravenous (IV) fluid bolus</li> <li>• Reduce frequency of uterine contractions</li> </ul> |
| <b>Reduce uterine activity</b>  | <ul style="list-style-type: none"> <li>• Tachysystole with Category II or III tracing</li> </ul>  | <ul style="list-style-type: none"> <li>• Discontinue oxytocin or cervical ripening agents</li> <li>• Administer tocolytic medication</li> </ul>  |
| <b>Alleviate umbilical cord compression</b>                           | <ul style="list-style-type: none"> <li>• Recurrent variable decelerations</li> <li>• Prolonged deceleration</li> <li>• Fetal bradycardia</li> </ul>                                       | <ul style="list-style-type: none"> <li>• Reposition the woman in a lateral or knee-chest position</li> <li>• Perform amnioinfusion</li> <li>• If cord prolapse, keep presenting fetal part elevated away from the cord</li> </ul>  |
| <b>Normalize maternal hypotension</b>                                 | <ul style="list-style-type: none"> <li>• Recurrent late decelerations</li> <li>• Prolonged decelerations</li> <li>• Fetal bradycardia</li> <li>• Category II or III tracings</li> </ul>   | <ul style="list-style-type: none"> <li>• Lateral position</li> <li>• IV fluids</li> <li>• If FHR not improving with other interventions, consider Ephedrin 5.0 to 10.0mg intravenous push (IVP)</li> </ul>   |

## General Principles of Evaluation and Management Include:

Administer oxygen at 8 to 10L/min via non-rebreather mask.

- There is controversy over the benefits and potential harms of oxygen therapy due to generation of free radicals; however, this remains a standard practice when FHR abnormalities occur [49,50].
- Observational studies have noted maternal oxygen administration can improve fetal oxygenation and decrease the frequency of late fetal decelerations [51-53]. There are no randomized trials evaluating oxygen therapy alone for treatment of category II and III tracings [54].
- Within 8 to 10 minutes of maternal oxygen administration, the fetal pO<sub>2</sub> and oxygen saturation reaches a higher level. These levels both decrease after supplemental maternal oxygen is removed [55-60].
- The effect of fetal pH related to maternal oxygen supplementation is weak and inconsistent [57-59,61-63].
- Fetal acidemia cannot be corrected by administering oxygen to the woman alone, the underlying cause of fetal hypoxemia needs to be corrected [64].



*Click the arrows  
to see more principles.*



## General Principles of Evaluation and Management Include:

Administer a bolus of 500 to 1000mL of lactated Ringer's or normal saline solution:

- Improved fetal oxygenation is noted on the FHR tracing as a result of increased placental blood flow when the hypovolemic woman receives an intravenous (IV) fluid bolus of non-glucose crystalloid [55, 57].
- Women with preeclampsia, cardiovascular disease, or those receiving beta-adrenergic drugs for tocolysis should receive IV fluids with caution. These women are at increased risk of volume overload.



*Click the arrows to see more principles.*



## General Principles of Evaluation and Management Include:

### Discontinue Uterotonic Drugs

- If tachysystole occurs, which is 5 contractions in 10 minutes, averaged over a 30 minute window, uterotonic drugs can be decreased or stopped [30].
- When uterine contractions occur there is an interruption of blood flow to the intervillous space. When tachysystole occurs the fetus may develop fetal hypoxemia [65].
- If decreasing the uterotonic drug does not result in decreased uterine contractions, it is recommended the drug be discontinued completely. If discontinuing the uterotonic drug does not result in decreased uterine contractions, it is recommended to administer a tocolytic drug. Terbutaline 250mcg subcutaneously, as a uterine relaxation medication, may improve placental blood flow and improve fetal oxygenation [65].



*Click the arrows  
to see more principles.*





## General Principles of Evaluation and Management Include:

### Women Who Have Recently Received Epidural Analgesia for Labor Pain Management:

- Following epidural analgesia, the women's blood pressure is monitored. If maternal hypotension occurs an alpha adrenergic agonist, such as phenylephrine or ephedrine, could be considered. This medication, along with an IV fluid bolus, may be corrective and improve uteroplacental blood flow.
- If mild or marked maternal hypotension occurs, the FHR may decelerate due to reduced placental perfusion.
- Alpha-adrenergic agonists phenylephrine or ephedrine, should be administered by a health care provider with expertise in the dosing and side effects of these medications.



*Click the arrows to see more principles.*



## General Principles of Evaluation and Management Include:

- 
- 
- Reassessment will help to determine if a cesarean section or operative vaginal delivery is needed.
  - When a decision is made for delivery, rapid intervention is needed.
  - When a Category II tracing is identified, it is important to determine those fetuses who are hypoxic with the small number of fetuses who are at risk for acidosis, neurologic impairment, or death.
    - Recall the likelihood of fetal acidosis is greater in a fetus with a Category III tracing than one with a Category II tracing.
  - If the FHR pattern does not improve within a few minutes, perform ancillary tests to provide better information about the fetal condition.



*Click the arrows  
to see more principles.*



## General Principles of Evaluation and Management Include:

- 
- The key observation is to determine if FHR accelerations are present and 15 bpm or more above the baseline and last for 15 seconds or more. This assures the absence of fetal acidosis [36,37].
  - Accelerations in the heart rate of a fetus <32 weeks which are 10 bpm or more above the baseline for 10 seconds or more assures there is absence of fetal acidosis [12].
  - If accelerations are not observed, they should be elicited by manual or vibro-acoustic stimulation.
  - When FHR accelerations are stimulated, the fetal pH is >7.20 in over 90% of the cases, and when no FHR accelerations occur the pH is <7.20 in approximately 50% of the cases [35,66-69].
- 



*Click the arrows  
to see more principles.*



## General Principles of Evaluation and Management Include:

- 
- If accelerations cannot be elicited, further evaluation by fetal ST analysis or direct access to fetal blood is indicated to help clarify the fetal acid-base status, if available. However, these modalities are not widely available.
  - Close observation and surveillance are recommended until a Category II tracing improves to a Category I or progresses to a Category III tracing. To date there is no data to outline how long to monitor a fetus with a persistent Category II tracing with the use of standard interventions.
  - Continuous monitoring and repeat testing is advised if the pattern persists since test results reflect acute fetal status at the time of the test, and may worsen over time.
- 



*Click the arrows  
to see more principles.*





## General Principles of Evaluation and Management Include:

### FHR Response to Stimulation

- The fetal scalp stimulation maneuver is easy to perform, inexpensive, readily available, and not uncomfortable.
- Fetal scalp stimulation can be elicited with digital scalp stimulation, vibroacoustic stimulation, fetal scalp puncture, or Allis clamp scalp stimulation [67].
- Scalp stimulation should be performed when the FHR is at its baseline rate.
- Fetal scalp stimulation performed during a FHR deceleration is not predictive of fetal acid-base status, will not terminate the deceleration, and may further compromise the fetus.



*Click the arrows to see more principles.*





## General Principles of Evaluation and Management Include:

### STAN Fetal Heart Monitor (ST Analysis)

- A technical system, the STAN S31 fetal heart monitor, monitors the fetal electrocardiogram (ECG) during labor.
- Use of this device is based on the principle that fetal hypoxemia can result in elevation or depression of the ST segment.
- Clinicians using this device should be trained and credentialed in its use and interpretation.
- There is inadequate clinical and cost data from a variety of hospital settings to allow a recommendation for routine use.



*Click the arrows to see more principles.*



## General Principles of Evaluation and Management Include:

### Fetal Scalp Blood Sampling

- Fetal blood sampling is typically performed using a kit, which is no longer manufactured in the United States.
- An amnioscope with a light source is inserted into the vagina and used to expose the fetal scalp. The fetal scalp is then cleansed of blood, mucous, and amniotic fluid.
- A smear of silicone gel is applied to the fetal scalp. This will allow for a droplet of blood to form when the fetal scalp is punctured. Generally, a 2-mm blade is used to make the puncture.
- Long heparinized capillary tubes are used to collect a blood sample.
- The woman must be dilated 2 to 3 cm before this test can be performed. Performing prior to 2 to 3 cm can be difficult and cause maternal discomfort.
- This test is contraindicated if the woman has a transmissible infection, such as HIV or hepatitis, or if the fetus has increased risk of a bleeding disorder.



*Click the arrows to see more principles.*



## General Principles of Evaluation and Management Include:

### Fetal Scalp Blood Sampling - Continued

- 
- Both pH and lactate measurements require the same laboratory facilities for microsample analysis.
  - Quality control and laboratory standards must be in place to utilize these tests, and most obstetrical services in the United States cannot support them, even when shared with neonatology.
  - Most hospitals have centralized laboratories for these tests and cannot function in a logistically efficient way for patients in labor.
  - The degree of technical skill required, cost, need for continuous availability of standardized equipment and trained personnel, and patient discomfort have precluded use of these tests in many labor and delivery units, despite their proven benefit in diagnosing fetal acidosis.
- 




*Click the arrows  
to see more principles.*



## General Principles of Evaluation and Management Include:

### Fetal Pulse Oximetry

- 
- Fetal pulse oximetry has no convincing evidence that assessment of fetal oxygen saturation by this technique as an adjunct to electronic FHR monitoring improves maternal or neonatal outcomes.
  - In a 2014 systematic review and meta-analysis of randomized trials, fetal pulse oximetry had no correlation with the overall cesarean section delivery rate nor were infant or maternal outcomes evaluated [69,70].



External monitoring is as reliable as internal monitoring in most cases [71].

Internal monitoring may be needed when the external tracing is difficult to interpret because of poor quality.

Poor quality external tracing may be a result of prematurity, multiple gestation, maternal obesity, frequent maternal or fetal movement, uterine myomata, or polyhydramnios.





Noninvasive or external FHR monitoring can be performed with a Doppler ultrasound device on the maternal abdomen [72].

- The EFM detects FHR atrial and ventricular contractions and opening and closing of the valves to create a complex wave form tracing.
- The computer then detects the peak of the wave to calculate a mechanical R wave-to-R wave (RR) interval.
- Because of the inherent variation in the Doppler ultrasound signal, a computer calculates the FHR by averaging several consecutive RR intervals to minimize artifact. This is known as auto correlation.
- This results in a highly processed record that smooths out signal variation and produces a processed sound, which is not the actual fetal heart beat.




*Click the picture for more information.*





Noninvasive or external FHR monitoring can be performed with a Doppler ultrasound device on the maternal abdomen (continued) [72]:

- The FHR tracing closely resembles that derived from a fetal electrocardiogram, but there is more baseline variability inherent with the Doppler technique.
- The Monica AN24 is an alternative technology that requires several electrodes to be placed on the maternal abdomen. The electrodes detect the fetal RR interval.
- Wireless monitors enable FHR monitoring while the women is ambulating.
- Auscultation of the FHR using a fetal stethoscope is also possible, but is rarely used because it is impractical due to requiring one-to-one nursing, and provides no information about variability, presence or frequency of accelerations, or shape of decelerations.




A fetal electrocardiogram (ECG) can be obtained by placing a bipolar spiral electrode into the fetal scalp transcervically.

- A second reference electrode is placed on the maternal thigh to eliminate electrical interference from maternal cardiac activity.
- A computer calculates the FHR based on the RR interval based on QRS complex of an electrocardiogram.
- Artifact is minimal so the signal is very clear and provides accurate measurement of beat-to-beat variability without autocorrelation [73-74].



*Click here for more information.*





A fetal electrocardiogram (ECG) can be obtained by placing a bipolar spiral electrode into the fetal scalp transcervically:

- Application of artificial intelligence computer programs to fetal ECG signal processing has led to development of devices for overcoming the limitations of FHR pattern interpretation by humans observers [73-74].
- This has been made possible by technical improvements in signal acquisition and processing, and by algorithms for pattern interpretation based on standardization of visual pattern analysis and correlation with fetal scalp blood and umbilical artery pH determinations.
- The STAN monitor analyzes the fetal T wave and ST segment.

The United States has not widely adopted this and it remains under investigation.

## Recommendations from National Organizations



### **The American College of Obstetricians and Gynecologists (ACOG) [30]:**

- Either continuous electronic FHR monitoring or intermittent auscultation (or intermittent monitoring) is acceptable in uncomplicated patients.
- High risk pregnancies (e.g., preeclampsia, suspected growth restriction, type 1 diabetes mellitus) should be monitored continuously during labor.

### **National Institute for Health Care Excellence:**

- In all birth settings, offer intermittent auscultation to low-risk women in the first stage of labor. Do not perform cardiotocography in low-risk women.
- Advise continuous cardiotocography if any of the following risk factors occur during labor:
  - Suspected chorioamnionitis, sepsis, or temperature  $\geq 38^{\circ}\text{C}$
  - Severe hypertension ( $\geq 160/110\text{mmHg}$ )
  - Oxytocin use
  - Significant meconium
  - Fresh vaginal bleeding

If continuous cardiotocography was used because of concerns arising from intermittent auscultation, but the tracing is normal after 20 minutes of observation, remove the cardiotocograph and return to intermittent auscultation.




- Two commonly used modalities for intrapartum FHR monitoring are continuous electronic FHR monitoring and intermittent auscultation/monitoring. The body of evidence indicates that neither test performs better than the other.
- Medical and legal views in the United States make some form of intrapartum FHR monitoring mandatory. Continuous electronic FHR monitoring is recommended for high-risk pregnant women.
- For the low-risk pregnant woman, intermittent or continuous electronic FHR monitoring is reasonable.
- Intrapartum FHR monitoring is usually not performed when a pregnancy is at a gestation age below the limit of viability or the fetus has an untreatable anomaly lethal in the newborn.



*Click each box for more information.*





The National Institutes of Child Health and Human Development (NICHD) definitions of FHR characteristics and their three-tier approach for interpreting fetal heart rate patterns ([Table 2](#)) and managing pregnancies with these patterns ([Table 3](#)) is generally agreeable.

However, it seems prudent to manage pregnancies with minimal variability similar to those with absent variability.

Use of this standardized approach to pattern recognition coupled with a standardized package of therapeutic interventions may improve neonatal outcomes.



*Click each box for more information.*



| <b>Category</b>           | <b>Interpretation</b>  | <b>Features</b>   |
|---------------------------|--|---|
| <b>I - Normal</b>         | Strongly predictive of normal acid-base status at this time of observation   | <ul style="list-style-type: none"> <li>• Baseline FHR 110-160 bpm</li> <li>• Baseline FHR variability moderate 6 to 25 bpm</li> <li>• Late or variable FHR decelerations are absent</li> <li>• Early FHR decelerations are present or absent</li> </ul>   |
| <b>II - Indeterminate</b> | Not predictive of abnormal acid-base status, however there are insufficient data to classify as either Category I or III | <p>All FHR tracings not categorized as Category I or III may represent many tracings that are encountered in everyday clinical practice.</p> <p>Examples:</p> <ul style="list-style-type: none"> <li>• Minimal variability</li> <li>• Absent variability without recurrent decelerations</li> <li>• Marked variability</li> <li>• Absent of induced accelerations after fetal stimulation</li> <li>• Prolonged deceleration</li> <li>• Recurrent late decelerations with moderate variability</li> <li>• Variable decels with "slow return to baseline," "overshoots" or "shoulders"</li> </ul> |
| <b>III - Abnormal</b>     | Predictive of abnormal acid-base status at time of observation   | <p>Absent FHR variability AND any of the following:</p> <ul style="list-style-type: none"> <li>• Recurrent late FHR decelerations</li> <li>• Recurrent variable FHR decelerations</li> <li>• FHR bradycardia</li> <li>• Sinusoidal FHR pattern</li> </ul>   |

| <b>Goal</b>   | <b>FHR Abnormality</b>  | <b>Intervention</b>  |
|---|---|--|
| <b>Promote fetal oxygenation and improve blood flow to the uterus</b> | <ul style="list-style-type: none"> <li>• Recurrent late decelerations</li> <li>• Prolonged decelerations</li> <li>• Fetal bradycardia</li> <li>• Minimal or absent variability</li> </ul> | <ul style="list-style-type: none"> <li>• Reposition the woman in a lateral position. If in a lateral position, change her to the other side.</li> <li>• Oxygen (O<sub>2</sub>) administration</li> <li>• Intravenous (IV) fluid bolus</li> <li>• Reduce frequency of uterine contractions</li> </ul> |
| <b>Reduce uterine activity</b>  | <ul style="list-style-type: none"> <li>• Tachysystole with Category II or III tracing</li> </ul>  | <ul style="list-style-type: none"> <li>• Discontinue oxytocin or cervical ripening agents</li> <li>• Administer tocolytic medication</li> </ul>  |
| <b>Alleviate umbilical cord compression</b>                           | <ul style="list-style-type: none"> <li>• Recurrent variable decelerations</li> <li>• Prolonged deceleration</li> <li>• Fetal bradycardia</li> </ul>                                       | <ul style="list-style-type: none"> <li>• Reposition the woman in a lateral or knee-chest position</li> <li>• Perform amnioinfusion</li> <li>• If cord prolapse, keep presenting fetal part elevated away from the cord</li> </ul>  |
| <b>Normalize maternal hypotension</b>                                 | <ul style="list-style-type: none"> <li>• Recurrent late decelerations</li> <li>• Prolonged decelerations</li> <li>• Fetal bradycardia</li> <li>• Category II or III tracings</li> </ul>   | <ul style="list-style-type: none"> <li>• Lateral position</li> <li>• IV fluids</li> <li>• If FHR not improving with other interventions, consider Ephedrin 5.0 to 10.0mg intravenous push (IVP)</li> </ul>   |



FHR abnormalities can be related to multiple factors other than hypoxemia.

A major goal of intrapartum fetal monitoring is to distinguish the large number of fetuses with Category II tracings who are hypoxemic, but well compensated, from the small number who are at risk of acidosis or death. This is also true for Category III tracings, except the likelihood of fetal acidosis is much higher with this pattern than with category II tracings. Further evaluation using ancillary tests may be useful.



*Click each box for more information.*





A key step in evaluation of a Category II or III FHR tracing is to determine if accelerations are present as a rise of  $\geq 15$  beats per minute above baseline lasting for  $\geq 15$  seconds almost always assures the absence of fetal acidosis. If accelerations are not observed, they should be elicited with manual or vibroacoustic stimulation.

When accelerations are induced in this setting, the fetal pH is  $>7.20$  in over 90% of cases, and when no accelerations occur, pH is  $<7.20$  in approximately 50% of cases.

If accelerations cannot be elicited, if available, further evaluation by fetal ST analysis or direct access to fetal blood is indicated to help clarify the fetal acid-base status.

Determine the cause of the abnormal FHR tracing and initiate corrective interventions such as discontinuing uterotonic drugs, changing the maternal position, administering an IV fluid bolus, and providing maternal oxygen supplementation.



*Click each box for more information.*






Transient episodes of hypoxemia, such as during a contraction or temporary cord compression, are generally well-tolerated by the fetus.

Repeated or prolonged episodes, especially if severe, may lead to fetal acidosis. Further evaluation of a Category II and III FHR tracings is indicated to distinguish the fetus who is not hypoxemic, or hypoxemic but well compensated, from one who is acidotic.

Assessing the FHR response to stimulation is a readily available method of fetal assessment that is easy to perform, inexpensive, and comfortable for the patient.





# Congratulations!

You have successfully completed this module.

*Click on the above 'X' to take the post-test for this course.  
If you do not attain a passing score after two attempts at the post-test  
the entire program must be repurchased.*

1. Practice bulletin no. 145: antepartum fetal surveillance. *Obstet Gynecol* 2014; 124:182.
2. Goetzl L. Adverse pregnancy outcomes after abnormal first-trimester screening for aneuploidy. *Clin Lab Med* 2010; 30:613.
3. Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. *J Obstet Gynaecol Can* 2008; 30:918.
4. Gardosi J, Madurasinghe V, Williams M, et al. Maternal and fetal risk factors for stillbirth: population-based study. *BMJ* 2013; 346: f108.
5. Vintzileos AM, Nochimson DJ, Guzman ER, et al. Intrapartum electronic fetal heart rate monitoring versus intermittent auscultation: a meta-analysis. *Obstet Gynecol* 1995; 85:149.
6. Nelson KB, Dambrosia JM, Ting TY, Grether JK. Uncertain value of electronic fetal monitoring in predicting cerebral palsy. *N Engl J Med*. 1996;334(10):613.
7. Grimes DA, Peipert JF. Electronic fetal monitoring as a public health screening program: the arithmetic of failure. *Obstet Gynecol*. 2010 Dec;116(6):1397-400.
8. Alfirevic Z, Devane D, Gyte GM, Cuthbert A. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. *Cochrane Database Syst Rev*. 2017;2:CD006066. Epub 2017 Feb 3.
9. Grant A, O'Brien N, Joy MT, Hennessy E, MacDonald D. Cerebral palsy among children born during the Dublin randomised trial of intrapartum monitoring. *Lancet*. 1989 Nov;2(8674):1233-6.
10. Phelan JP, Kim JO. Fetal heart rate observations in the brain-damaged infant. *Semin Perinatol*. Graham EM, Petersen SM, Christo DK, Fox HE. Intrapartum electronic fetal heart rate monitoring and the prevention of perinatal brain injury. *Obstet Gynecol*. 2006;108(3 Pt 1):656.
11. Graham EM, Petersen SM, Christo DK, Fox HE. Intrapartum electronic fetal heart rate monitoring and the prevention of perinatal brain injury. *Obstet Gynecol* 2006; 108:656.
12. Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. *Obstet Gynecol* 2008; 112:661.
13. Cahill, A. G., Rowhl, K. A., Odibo, A. O., Macones, G. A. Association and prediction of acidemia. *Am J Obstet Gynecol* 2012; 207;206.e1.
14. Westgate JA, Wibbens B, Bennet L, et al. The intrapartum deceleration in center stage: a physiologic approach to the interpretation of fetal heart rate changes in labor. *Am J Obstet Gynecol* 2007; 197:236.e1.
15. Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. *Am J Obstet Gynecol* 1997; 177:1385.
16. Frasch, M. G., Mansano, R. Z., McPhaul, L., et al. Measures of acidosis with repetitive umbilical cord occlusions leading to fetal asphyxia in the near-term ovine fetus. *Am J Obstet Gynecol* 2009; 200:200.e1.
17. Ross, M. G., Jessie, M., Amaya, K., et al. Correlation of arterial fetal base deficit and lactate changes with severity of variable heart rate decelerations in the near-term ovine fetus. *Am J Obstet Gynecol* 2013, 208:285.e1.

18. Young, B. K., Katz, M., Wilson, S. J. Sinusoidal fetal heart rate. I. Clinical significance Am J Obstet Gynecol 1980; 136:587.
19. Katz, M., Wilson, S. J., Young, B. K. Sinusoidal fetal heart rate. II. Continuous tissue pH studies. Am J Obstet Gynecol 1980; 36:594.
20. Johnson, T. R. Jr., Compton, A. A., Rotmensch, J., et al. Significance of the sinusoidal fetal heart rate pattern. Am J Obstet Gynecol 1981; 139:446.
21. Murotsuki, J., Kimura, Y., Iwamoto, M., et al. Power spectral analysis of spontaneous rhythm in peripheral blood flow in fetal lamb. Nihon Sanka Fujinka, Gakkai, Zasshi 1993; 45:1394.
22. Van Woerden, E. E., van Geijn, H. P., Swarties, J. M., et al. Fetal heart rhythms during behavioural state 1F. Eur J Obstet Gynecol Reprod Biol 1988; 28:29.6.
23. Nielsen, P. V., Stigsby, B., Nickelsen, C., Nim, J. Intra- and inter-observer variability in the assessment of intrapartum cardiotocograms. Acta Obstet Gynecol Scand 1987; 66:421.
24. Beaulieu, M. D., Fabia, J., Leduc, B., et al. The reproducibility of intrapartum cardiotocogram assessments. Can Med Assoc J 1982; 127:214.
25. Chauhan, S. P., Klausner, C. K., Woodring, T. C., et al. Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes: interobserver variability. Am J Obstet Gynecol 2008; 199:623.e1.
26. Blackwell, S. C., Grobman, W. A., Antoniewicz, L., et al. Interobserver and intraobserver reliability of the NICHD 3-Tier Fetal Heart Rate Interpretation System. Am J Obstet Gynecol 2011; 205:378.e1.
27. Schiermeier, S., Westhof, G., Leven, A., et al. Intra- and interobserver variability of intrapartum cardiotocography: a multicenter study comparing the FIGO classification with computer analysis software. Gynecol Obstet Invest 2011; 72:169.
28. Rhöse, S., Heinis, A. M., Vandenbussche, F., et al. Inter- and intra-observer agreement of non-reassuring cardiotocography analysis and subsequent clinical management. Acta Obstet Gynecol Scand 2014; 93:596.
29. Clark, S. L., Nageotte, M. P., Garite, T. J., et al. Intrapartum management of category II fetal heart rate tracings: towards standardization of care. Am J Obstet Gynecol 2013; 209:89.
30. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol. 2009;114(1):192. Reaffirmed 2017.
31. Electronic fetal heart rate monitoring, research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385.
32. Ayres-de-Campos D, Spong CY, Chandrharan E, FIGO Intrapartum Fetal Monitoring Expert Consensus Panel. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography. Int J Gynaecol Obstet. 2015;131(1):13.
33. Clark, S. L., Meyers, J. A., Frye, D. K., et al. Recognition and response to electronic fetal heart rate patterns: impact on newborn outcomes and primary cesarean delivery rate in women undergoing induction of labor. Am J Obstet Gynecol 2015; 212:494.el.
34. Clark SL, Nageotte MP, Garite TJ, et al. Intrapartum management of category II fetal heart rate tracings: towards standardization of care. Am J Obstet Gynecol 2013; 209:89.

35. Clark, S. L., Gimovsky, M. L., Miller, F. C. The scalp stimulation test.: a clinical alternative to fetal scalp blood sampling. *Am J Obstet Gynecol* 1984; 148:274.
36. Krebs, H. B., Petres, R. E., Dunn, L. J., Smith, P. J. Intrapartum fetal heart rate monitoring VI. Prognostic significance of accelerations. *Am J. Obstet Gynecol* 1982; 142:297.
37. Powell, O. H., Melville, A., MacKenna, J. Fetal heart rate acceleration in labor: excellent prognostic indicator. *Am J Obstet Gynecol* 1979; 134:36.
38. Jackson M, Holmgren CM, Esplin MS, et al. Frequency of fetal heart rate categories and short-term neonatal outcome. *Obstet Gynecol* 2011; 118:803.
39. Liston R, Sawchuck D, Young D, et al. Fetal health surveillance: antepartum and intrapartum consensus guideline. *J Obstet Gynaecol Can* 2007; 29:S3.
40. Paquette S, Moretti F, O'Reilly K, et al. The incidence of maternal artefact during intrapartum fetal heart rate monitoring. *J Obstet Gynaecol Can* 2014; 36:962.
41. Sherman DJ, Frenkel E, Kurzweil Y, et al. Characteristics of maternal heart rate patterns during labor and delivery. *Obstet Gynecol* 2002; 99:542.
42. VAN Veen TR, Belfort MA, Kofford S. Maternal heart rate patterns in the first and second stages of labor. *Acta Obstet Gynecol Scand* 2012; 91:598.
43. Neilson DR Jr, Freeman RK, Mangan S. Signal ambiguity resulting in unexpected outcome with external fetal heart rate monitoring. *Am J Obstet Gynecol* 2008; 198:717.
44. McWhinney NA, Knowles S, Green HL, Gordon H. Transmission of the maternal electrocardiograph via a fetal scalp electrode in the presence of intrauterine death. Case report. *Br J Obstet Gynaecol* 1984; 91:1046.
45. Phelan JP, Ahn MO. Perinatal observations in forty-eight neurologically impaired term infants. *Am J Obstet Gynecol* 1994; 171:424.
46. Ahn MO, Korst LM, Phelan JP. Normal Fetal Heart Rate Pattern in the Brain-damaged Infant: A Failure of Intrapartum Fetal Monitoring? *J Matern Fetal Investig* 1998; 8:58.
47. Terao T, Kawashima Y, Noto H, et al. Neurological control of fetal heart rate in 20 cases of anencephalic fetuses. *Am J Obstet Gynecol* 1984; 149:201.
48. Reid DL, Parer JT, Williams K, et al. Effects of severe reduction in maternal placental blood flow on blood flow distribution in the sheep fetus. *J Dev Physiol* 1991; 15:183.
49. Hamel MS, Hughes BL, Rouse DJ. Whither oxygen for intrauterine resuscitation? *Am J Obstet Gynecol* 2015; 212:461.
50. Garite TJ, Nageotte MP, Parer JT. Should we really avoid giving oxygen to mothers with concerning fetal heart rate patterns? *Am J Obstet Gynecol* 2015; 212:459.
51. Althabe O Jr, Schwarcz RL, Pose SV, et al. Effects on fetal heart rate and fetal pO<sub>2</sub> of oxygen administration to the mother. *Am J Obstet Gynecol* 1967; 98:858.
52. Simpson KR. Intrauterine resuscitation during labor: review of current methods and supportive evidence. *J Midwifery Women's Health* 2007; 52:229.

53. Haydon ML, Gorenberg DM, Nageotte MP, et al. The effect of maternal oxygen administration on fetal pulse oximetry during labor in fetuses with nonreassuring fetal heart rate patterns. *Am J Obstet Gynecol* 2006; 195:735.
54. Fawole B, Hofmeyr GJ. Maternal oxygen administration for fetal distress. *Cochrane Database Syst Rev* 2012; 12:CD000136.
55. Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. *Obstet Gynecol* 2005; 105:1362.
56. McNamara H, Johnson N, Lilford R. The effect on fetal arteriolar oxygen saturation resulting from giving oxygen to the mother measured by pulse oximetry. *Br J Obstet Gynaecol* 1993; 100:446.
57. Thorp JA, Trobough T, Evans R, et al. The effect of maternal oxygen administration during the second stage of labor on umbilical cord blood gas values: a randomized controlled prospective trial. *Am J Obstet Gynecol* 1995; 172:465.
58. Khazin AF, Hon EH, Hehre FW. Effects of maternal hyperoxia on the fetus. I. Oxygen tension. *Am J Obstet Gynecol* 1971; 109:628.
59. Morishima HO, Daniel SS, Richards RT, James LS. The effect of increased maternal PaO<sub>2</sub> upon the fetus during labor. *Am J Obstet Gynecol* 1975; 123:257.
60. Antoine C, Young BK, Silverman F. Simultaneous measurement of fetal tissue pH and transcutaneous pO<sub>2</sub> during labor. *Eur J Obstet Gynecol Reprod Biol* 1984; 17:69.
61. Suidan JS, Antoine C, Silverman F, et al. Human maternal-fetal lactate relationships. *J Perinat Med* 1984; 12:211.
62. Newman W, McKinnon L, Phillips L, et al. Oxygen transfer from mother to fetus during labor. *Am J Obstet Gynecol* 1967; 99:61.
63. Sirimai K, Atisook R, Boriboonhirunsam D. The correlation of intrapartum maternal oxygen administration and umbilical cord blood gas values. *Acta Obstet Gynecol Scand Suppl* 1997; 76:90.
64. Hamel MS, Anderson BL, Rouse DJ. Oxygen for intrauterine resuscitation: of unproved benefit and potentially harmful. *Am J Obstet Gynecol* 2014; 211:124.
65. Kulier R, Hofmeyr GJ. Tocolytics for suspected intrapartum fetal distress. *Cochrane Database Syst Rev* 2000; CD000035.
66. Smith CV, Nguyen HN, Phelan JP, Paul RH. Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations. *Am J Obstet Gynecol* 1986; 155:726.
67. Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. *Obstet Gynecol* 2002; 99:129.
68. Edersheim TG, Hutson JM, Druzin ML, Kogut EA. Fetal heart rate response to vibratory acoustic stimulation predicts fetal pH in labor. *Am J Obstet Gynecol* 1987; 157:1557.
69. Trochez RD, Sibanda T, Sharma R, Draycott T. Fetal monitoring in labor: are accelerations good enough? *J Matern Fetal Neonatal Med* 2005; 18:349.
70. East CE, Begg L, Colditz PB, Lau R. Fetal pulse oximetry for fetal assessment in labour. *Cochrane Database Syst Rev* 2014:CD004075.

71. Bakker JJ, Janssen PF, van Halem K, et al. Internal versus external tocodynamometry during induced or augmented labour. *Cochrane Database Syst Rev* 2013;CD006947.

72. Boatin AA, Wylie B, Goldfarb I, et al. Wireless fetal heart rate monitoring in inpatient full-term pregnant women: testing functionality and acceptability. *PLoS One* 2015; 10: e0117043.

73. Liszka-Hackzell JJ. Categorization of fetal heart rate patterns using neural networks. *J Med Syst* 2001; 25:269.

74. Czabański R, Jezewski J, Wróbel J, et al. Application of fuzzy inference systems for classification of fetal heart rate tracings in relation to neonatal outcome. *Ginekol Pol* 2013; 84:38.